Posts Tagged ‘smoking cessation’
Could I be wrong? Exploring cognitive bias, curiosity, intellectual humility, and lifelong learning
Welcome to a new edition of SharpBrains’ e‑newsletter, featuring eight timely scientific and industry news plus a few fun teasers to appreciate our unique human brains. #1. Could I be wrong? Exploring research on cognitive bias, curiosity, intellectual humility, and lifelong learning “None of us thinks that our beliefs and attitudes are incorrect; if we…
Read MoreClick Therapeutics raises further $52M to build up digital therapeutics pipeline for depression, insomnia, smoking cessation and more
With Sanofi still on board, Click Therapeutics closes $52M series B for digital therapeutics in depression, chronic pain and more (Fierce Biotech): Another medtech developer’s plans to create digital therapeutics to treat a wide range of illnesses are clicking into place, thanks to a third multimillion-dollar investment in Click Therapeutics in barely a year.
Read MoreHow to intervene early to address brain/ mental health problems: Examples in depression, epilepsy and smoking cessation
How to intervene early: Examples in depression, epilepsy and smoking cessation from SharpBrains We hope you enjoy this slidedeck supporting a fascinating, forward-looking session held at the 2019 SharpBrains Virtual Summit: The Future of Brain Health (March 7–9th). Full recordings are available for purchase here. 10.45am-12.15pm. How to intervene early: Examples in depression, epilepsy and smoking cessation Dr. Walter Greenleaf,…
Read MoreSanofi Ventures leads $17M investment in Click Therapeutics, finalist @ 2017 Brainnovations Pitch Contest
Sanofi Backs Click Therapeutics as Digital Medicines Gain Momentum (Xconomy): “Drug makers are making more bets on the nascent field of digital medicine. The latest example: Click Therapeutics announced Monday that it grabbed a $17 million investment led by Sanofi Ventures, the Cambridge, MA-based venture capital arm of the French pharmaceutical giant.
Read MoreSneak preview into the future of mental health: Fully digital clinical trials to study digital therapeutics
——– Click Therapeutics™ Reports Preliminary Results of a 416-Participant Clinical Study Demonstrating Exceptional Engagement and Efficacy of Clickotine®, a Patent-Pending Digital Therapeutics™ Program for Smoking Cessation (press release): “Click Therapeutics, Inc. (“Click”), a company developing a suite of personalized data-driven digital therapeutics for chronic health conditions, announces today preliminary results of its fully remote clinical…
Read More